Purpose: Magnetic resonance imaging (MRI)-guided adaptive brachytherapy is the standard of care for cervical cancer. Hybrid intracavitary/interstitial applicators for bulky tumor (high-risk clinical target volume [HR-CTV] > 30 cc) dose escalation is recommended in the EMBRACE II trial. The value of hybrid applicators for smaller HR-CTV (< 30 cc) in organ at risk (OAR) sparing is less certain.
Purpose
Brachytherapy is of critical importance in the treatment of locally advanced cervical cancer. Treatment is performed using a variety of applicators and imaging modalities. Use of magnetic resonance imaging (MRI)based planning in defining the target volume has become more widely available and is preferred to computed tomography (CT) due to improved soft tissue resolution. Accurate target delineation and dose limiting toxicities remain a challenge with CT-based approaches [1, 2, 3] . A small prospective trial by Viswanathan et al. compared contours and dose volume histograms (DVH) of tumor and organs at risk (OAR) in cervical cancer brachytherapy. The MRI and CT DVH values for OAR were similar, but statistically significant differences were shown in the high-risk clinical target volume (HR-CTV) width when contoured on CT vs. MRI [4] . With improved target resolution, there has been increased interest in using customized hybrid intracavitary/interstitial applicators to customize dose for bulky tumors. Using MRI-based treat-ment planning techniques, hybrid applicators allow for an increase in target coverage, treated volume, and total dose without increasing the dose to critical structures [5] . The EMBRACE study has also provided a wealth of information regarding the clinical feasibility of hybrid intracavitary/interstitial applicators as well as improved DVH parameters and acceptable additional procedure time [6] . Based on the improvement in target dose and sparing of OAR found with the use of hybrid applicators in these studies, the GYN GEC-ESTRO dose constraints have been modified to support a higher HR-CTV D 90 value without a significant increase in dose to OAR [6] . Kirisits et al. showed that the use of a hybrid applicator for bulky tumors allows increases in target coverage, treated volume, and total dose without increasing the dose to critical structures [5] . The role of hybrid needle applicators in OAR dose reduction for small volume tumors is less clear. With increased understanding of potential toxicities with doses to organs at risk previously considered safe, the use of hybrid applicators in small volume tumors may also be applied to improve the therapeutic ratio. The purpose of this study was to evaluate the benefit of hybrid tandem and ring applicators in OAR sparing for small volume tumors.
Material and methods
Twenty seven consecutive patients who underwent high-dose-rate (HDR) brachytherapy for cervical cancer between September 2015 and October 2017 at the University of Cincinnati were retrospectively reviewed. All patients were re-planned at fraction 1 with the use of virtual needles. Virtual needles were placed using a template for the tandem and Vienna ring cap (Mick Radio-Nuclear Instruments, Inc.) hybrid applicator. Needle positions were determined based on the tumor and OAR anatomy ( Figure 1 ).
Needles were advanced to a maximum distance of 4 cm beyond the ring, and the first loading position was typically 2-3 mm back from the tip of the needle. Each fraction was then propagated to four total fractions (7 Gy × 4 fractions) and summed with the external beam dose using EQD 2 summation to evaluate differences in target coverage and organ at risk dose. Coverage of the HR-CTV and sparing of OARs was achieved by a graphical optimization method. All hybrid plans were compared to the actual plans treated without hybrid interstitial needles. A subset of small volume tumors < 30 cc were compared. Tumors less than 30 cc were defined as small or "limited" volume per the EMBRACE II protocol. The HR-CTV D 90 and D 2cc dose to bladder, rectum, and sigmoid were compared with a paired t-test. 
Results
Twenty-seven patients with International Federation of Gynecology and Obstetrics (FIGO) stage I-IVA cervical cancer were reviewed during the study period. The median age was 48 (range, 23-75). All patients were treated with definitive chemoradiation (45-50.4 Gy) and MRI-based brachytherapy using conventional tandem and ring applicators. Of the 27 patients, 24 (89%) had MRI-based brachytherapy planning defined as at least one MRI performed with the applicator in place. Of the 27 patients, 8 (30%) had FIGO stage I disease, 14 (52%) had stage II, 4 (15%) stage III, and 1 (3%) had stage IVA disease. For all patients, the median HR-CTV volume was 24.4 cc (16-55 cc). Twenty-two of the 27 patients (81%) had small volume tumors, with HR-CTV volumes < 30 cc. Eighteen of those twenty-two patients had an MRI fused for brachytherapy planning.
Each of the 27 patients underwent re-planning with placement of virtual needles at fraction one. The median number of needles used was 2 (range, [1] [2] [3] [4] . At least 2 virtual needles were used in planning for the majority of patients (1 needle, n = 1 (4%), 2 needles, n = 12 (44%), 3 needles, n = 7 (26%), 4 needles, n = 7 (22%)).
For all patients, the hybrid tandem and ring (TR) applicators had a lower mean D 2cc to the bladder (71 Gy vs. 86 Gy, p < 0.0001), rectum (57 Gy vs. 62 Gy, p < 0.0001), and sigmoid (64 Gy vs. 67 Gy, p = 0.0039) compared to conventional TR applicators, with no difference in HR-CTV D 90 coverage (93.4 vs. 94.5, p = 0.53) ( Table 1 ). In patients with HR-CTV < 30 cc, the hybrid TR applicators had a lower mean D 2cc to the bladder (70 Gy vs. 85 Gy, p < 0.0001), rectum (57 Gy vs. 62 Gy, p < 0.0001), and sigmoid (64 Gy vs. 67 Gy, p = 0.005) compared to conventional TR applicators, without difference in HR-CTV D 90 coverage (96 Gy vs. 94 Gy, p = 0.12) ( Table 2 ). In patients with HR-CTV < 30 cc, the D 2cc bladder goal of < 80 Gy as per EMBRACE II was exceeded in 1/22 (4.5%) of patients, with the hybrid TR applicators compared to 17/22 (77%) patients with conventional TR applicators (p = 0.0001). Similarly, more patients in the conventional TR group exceeded the D 2cc goal for rectum of 65 Gy (7/22, 32%) compared to the hybrid TR group (0/22, 0%) (p < 0.001). There was no difference in the proportion of patients with sigmoid D 2cc > 65 Gy in the conventional TR group (12/22, 59%) compared to the hybrid TR group (9/22, 41%) (p = 0.54). Figure 2 shows pre and post needle axial, coronal, and sagittal MRI images of the modification of dose.
Discussion
With the development of image-based adaptive brachytherapy for cervical cancer using MRI, uncertainties in target volumes and organs at risk have been reduced [7] . The ability to obtain essential information about tumor extent and response as well as to delineate structures utilizing adequate imaging protocols meets the demands for 3D image-based brachytherapy [8] . When analyzed systematically, MRI findings prior to external beam radiotherapy and at the time of brachytherapy provide this essential data [8, 9] . Areas of high and intermediate intensity that represent macroscopic and partly microscopic residual disease must be included in the HR-CTV per GEC-ESTRO guidelines [10, 11] . There have also been improvements in outcomes such as local control, overall survival, and morbidity with this MRI-based approach [12] . In 2008, the GEC-ESTRO GYN network initiated the EMBRACE study for the purpose of evaluating and benchmarking MRI-guided brachytherapy in a prospective multicenter fashion. Results from this study established a significant correlation between late rectal mor- bidity and dose volume parameters. They found a D 2cc ≤ 65 Gy to be associated with more minor and less frequent rectal morbidity, whereas a D 2cc ≥ 75 Gy was associated with more major and more frequent rectal morbidity [13] . When considering bladder toxicity, a significant dose relationship was also found, which indicated that at dose levels beyond 80 Gy EQD 2 , there was a clinically significant increase in grade 2 or greater morbidity [14] . Similarly, Georg et al. showed that well defined dose response curves could be established for D 2cc in the rectum and urinary bladder. For rectal morbidity, they found a 5% incidence of G2 to G4 toxicity with a D 2cc dose of 67 Gy. There was a 5% incidence of G2 to G4 bladder complications with 70 Gy [15] .
In addition, there is promising data regarding the use of hybrid applicators based on a retrospective analysis of 610 patients from the RetroEMBRACE study. This cohort of patients with locally advanced cervical cancer was treated with IGABT based on MRI or CT. The study involved 2 groups, one in which hybrid applicators were used systematically in more than 20% of patients and an intracavitary group, which included patients who were treated before systemic use of hybrid applicators was implemented [16] . Approximately, three quarters of the patients had locally advanced disease and 82% received IGABT based on MRI, and combined IC/IS (intracavitary/interstitial) brachytherapy was used in total 24% of patients. Overall, 3-year and 5-year local control rates were 92% and 89%, respectively, and in the combined IC/IS group, 3-year and 5-year local control rates were 94% and 91%, respectively. When comparing the IC and the IC/IS groups, local control was 5% better in the IC/IS group. Similarly, when looking at two groups with HR-CTV volume ≥ 30 cc and < 30 cc, local control was again found to be superior in the IC/IS group at 92% and 87% at 3 and 5 years for large tumors. By comparison, the IC only group had 82% and 80% local control rates for large tumors. This difference resulted in a significant 3-year and 5-year survival difference of 10% and 7% between the groups. For small tumors (< 30 cc), local control in the IC/IS group was 97% at 3 and 5 years compared to 96% and 93% in the IC group. In contrast to that of large tumors, there was no significant difference found [16] .
Based on this data, there is now sufficient evidence for the use of hybrid intracavitary/interstitial applicators for tumor control for large volume tumors. The EMBRACE II protocol has decreased the desired OAR goals for bladder and rectum in hope of decreasing the morbidity of therapy. The Bladder D 2cc goal was decreased to 80 Gy compared to 90 Gy in the EMBRACE I with hope of lowering grade 2 or higher urinary toxicity to 21% and grade 3 or higher urinary toxicity to 6%. The rectal D 2cc goal was decreased to < 65 Gy in the EMBRACE II compared to 70 Gy in the EMBRACE I protocol, with the goal of lowering grade 2 or higher rectal toxicity to 9% and grade 3 or higher rectal toxicity to 2%. Mazeron et al. have reported, based on the EMBRACE cohort, that a D 2cc rectal dose greater than or equal to 75 Gy was associated with a 12.5% risk of fistula at 3 years compared to 0-2.7% at lower doses. A D 2cc dose of less than 65 Gy was associated with a twofold lower risk of proctitis than 65 Gy or greater [13] .
These new GYN GEC ESTRO OAR parameters may be difficult to meet with conventional TR methods. This is evidenced by the results of our study in small volume tumors showing the D 2cc bladder goal of < 80 Gy was exceeded in 4.5% of patients with the hybrid TR applicators vs. 77% of patients with conventional TR applicators. Additionally, more patients in our conventional TR group exceeded the D 2cc goal for rectum of 65 Gy at 32% compared to the hybrid TR group at 0%.
Potential areas of weakness in our study include the small sample size from a single institution and the ret-rospective nature of the study. In addition, the generated hybrid plans were idealized virtual plans. The needle placement in virtual plans may be more difficult to achieve in practice. Lastly, vaginal doses were not analyzed in our study.
Conclusions
Hybrid intracavitary/interstitial applicators are an invaluable tool for enhancing HR-CTV coverage and escalating dose in large volume cervical cancers without an increase in the dose to critical structures.
The results of our study support the use of hybrid applicators in patients with small volume HR-CTVs and suggest that the EMBRACE II constraints will be met in a greater proportion of patients. Whether these potential dosimetric advantages will result in lower rates toxicity rates will need to be evaluated clinically.
